74919-31-6 Usage
General Description
2-Ethoxy-3-bromo-5-nitropyridine is a chemical compound with the molecular formula C7H7BrN2O3. It is a pale yellow solid that is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceutical compounds. The compound is known for its selective reactivity and is often used as a building block in the production of drugs and agrochemicals. Its unique combination of ethoxy, bromo, and nitro functional groups make it a versatile chemical that is valued for its ability to be easily modified and incorporated into various synthetic routes. The compound is also used in research and development as a reagent in organic synthesis. Additionally, it is an important starting material in the manufacturing of active pharmaceutical ingredients.
Check Digit Verification of cas no
The CAS Registry Mumber 74919-31-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,9,1 and 9 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 74919-31:
(7*7)+(6*4)+(5*9)+(4*1)+(3*9)+(2*3)+(1*1)=156
156 % 10 = 6
So 74919-31-6 is a valid CAS Registry Number.
InChI:InChI=1/C7H7BrN2O3/c1-2-13-7-6(8)3-5(4-9-7)10(11)12/h3-4H,2H2,1H3
74919-31-6Relevant articles and documents
NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
-
Paragraph 1173; 1174; 1177, (2018/09/08)
An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
